Basel, 04 February 2025- Roche announced today that the US Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision ...

Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for ...

Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...

Roche's (RHHBY) Genentech unit has received FDA approval for its eye drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema. Read more here.

Roche said that the Food and Drug Administration's decision was based on positive one-year results from the phase III of the Pagoda randomized study, which showed that Susvimo led to sustained ...

By Andrea Figueras Roche said its Susvimo drug received approval from the U.S. drug regulator for the treatment of diabetic retinopathy, a potentially blinding condition.

Susvimo (ranibizumab injection) was approved in the U.S. in October 2021 to treat wet AMD — a disease which affects the central part of the retina called macula and causes gradual vision loss.

On October 22, 2021 Roche announced the FDA’s approval of its ranibizumab intravitreal injection, marketed as Susvimo. Susvimo is a refillable ocular implant—requiring refills every six months ...

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary ...

Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...